Pediatric cancers are different from adult cancers, primarily because childhood cancers are extremely rare and complex, requiring a specialized team of healthcare professionals to care for a child with cancer. The University of Michigan C.S. Mott Children's Hospital Solid Tumor Oncology Program (M-STOP) is one of the largest pediatric oncology multidisciplinary teams in the United States, providing comprehensive care for all children with solid tumors including neuroblastoma, Wilms' tumor, liver tumors, and sarcomas.

“We have a true multidisciplinary program,” notes Assistant Professor of Pediatric Surgery, Erika Adams Newman, M.D. “Pediatric oncologists, surgeons, radiation oncologists, pathologists, radiologists, advanced practice nurses, and social workers attend regular tumor board meetings. Our team provides truly integrated, around-the-clock coordinated care, advancing all aspects of pediatric cancer treatment.”

“Our team approach is one of our most valuable tools in formulating the best treatment plan tailored to each patient’s needs,” Dr. Newman continues. “We utilize the most up-to-date technologies, including minimally invasive approaches for the advanced diagnosis and treatment of tumors.”

Advancing Care Through Science and Leadership

The C.S. Mott Children’s Hospital is one of the few centers around the country with a variety of national clinical trials available through the Children's Oncology Group – an organization funded through the National Institutes of Health. For families, this level of research activities provides unique access to the latest emerging therapies for many cancers. The Phase 1 Center, led by neuroblastoma expert Dr. Rajen Mody, offers hope for patients who have run out of standard options. Dr. Peter Ehrlich leads the renal tumors studies in the Children's Oncology Group and is a national expert in the care of children with advanced Wilms’ tumors. Dr. Brenda Kitchen, Dr. Aghiad Chamdin and Dr. Rama Jasty provide guidance for treating every solid tumor in childhood, particularly those children with aggressive or recurrent diseases.

Dr. James Geiger, the Executive Director of the Michigan's Medical Innovation Center is a national expert in neuroblastoma and is leading several initiatives in biomedical innovations to advance not only pediatric oncology, but to improve healthcare on a global scale.

“We have the skill and resources necessary to successfully address any form of children's cancer,” Dr. Newman says. “Our program is designed to give our patients the very best curative therapy available and deliver care in a personalized, family-centered environment.”

The children’s cancer program at C.S. Mott Children’s Hospital offers a full spectrum of care for pediatric cancer patients.

For more information, or to schedule a consultation, please call 1-475-MOTT
Visit the website at www.mottchildren.org